Safety and efficacy of ketamine-dexmedetomidine combination versus dexmedetomidine alone in cirrhotic patients undergoing upper gastrointestinal endoscopy: a prospective controlled clinical trial | ||||
| Ain-Shams Journal of Anesthesiology | ||||
| Volume 14, Issue 1, January 2022 PDF (1.11 MB) | ||||
| DOI: 10.1186/s42077-022-00222-5 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
H. S. Mohamed   ; O. H. Salman
| ||||
| Abstract | ||||
| Background Patients with liver cirrhosis commonly undergo diagnostic and/or therapeutic upper gastrointestinal endoscopy (UGIE). These fragile patients are at increased risk to develop complications as most sedative drugs are metabolized by the liver. Results UGIE could be performed effectively and safely with the KD ( = 35) group compared with the D group as no significant change in hemodynamics (HR and MBP) and O saturation (SPO) from baseline values ( value > 0.05) while the D group revealed a statistically significant drop in hemodynamic parameters when compared with the KD group ( value < 0.001). Conclusions The ketamine-dexmedetomidine sedo-analgesia group is highly effective than the dexmedetomidine-alone group in UGIE procedures with rapid induction time, good hemodynamic stability good recovery profile with less post-operative adverse effects. Trial registeration 1. IRB approval: 5 December 2016(Chairperson of Institutional Review Board of Ethics committee of Qena University Hospitals Prof. Ahmed Abuelyosr). The committee reference number is not applicable. 2. This study is registered in the Australian Newzeland Clinical Trial Registry (ANZCTR) at the number 12615000367549. Trial Id: , universal trial number(UTN): U1111-1165-6212. | ||||
| Keywords | ||||
| Dexmedetomidine; Ketamine; Ketodex; UGIE | ||||
|
Statistics Article View: 13 PDF Download: 13 |
||||
